A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug
Scott Berry(Queen's University), Michael Krams(Wellcome Centre for Human Neuroimaging), John Z. Liang(Pfizer (United States)), Roger Lewis(University of California, Los Angeles), Donald A. Berry(Berry & Associates (United States)), Parvin Fardipour(Pfizer (United States)), Gary S. Littman, Walter Spinelli(Pfizer (United States))
Cited by 42
Related Papers
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
|New England Journal of Medicine|2017|5.5k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980